Evidence map›Paper›PMID 35839054›Full record

ArticleMedicine2022

Fulminant elderly adult-onset Still disease effectively treated with tocilizumab and methotrexate: A case report.

Yugo Horiuchi, Kenichi Hashimoto, Hideyuki Horikoshi, Azusa Sano, Yusuke Kawamura, Naoya Fujita, Motohiro Kimata, Yosuke Ono, Yasuhiro Obuchi, Arisa Makino and 4 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Adjunctive Therapeutic Plasma Exchange in Refractory Adult-Onset Still's Disease Complicated by Secondary Macrophage Activation Syndrome: A Single-Center Experience.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Yugo HoriuchiDepartment of General Medicine, National Defense Medical College, Tokorozawa, Saitama.
Kenichi HashimotoDepartment of General Medicine, National Defense Medical College, Tokorozawa, Saitama.ORCID 0000-0001-6838-1215
Hideyuki HorikoshiDivision of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama.
Azusa SanoDepartment of General Medicine, National Defense Medical College, Tokorozawa, Saitama.
Yusuke KawamuraDepartment of General Medicine, National Defense Medical College, Tokorozawa, Saitama.
Naoya FujitaDepartment of General Medicine, National Defense Medical College, Tokorozawa, Saitama.
Motohiro KimataDepartment of General Medicine, National Defense Medical College, Tokorozawa, Saitama.
Yosuke OnoDepartment of General Medicine, National Defense Medical College, Tokorozawa, Saitama.
Yasuhiro ObuchiDepartment of General Medicine, National Defense Medical College, Tokorozawa, Saitama.
Arisa MakinoDepartment of Traumatology and Critical Care Medicine, National Defense Medical College, Tokorozawa, Saitama.
Mayuko KanekoDepartment of Traumatology and Critical Care Medicine, National Defense Medical College, Tokorozawa, Saitama.
Fumihiko KimuraDivision of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama.
Kenji ItohDivision of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama.
Yuji TanakaDepartment of General Medicine, National Defense Medical College, Tokorozawa, Saitama.
New York Times · USNational Defense Medical College · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleAdult-onset Still disease (AOSD) is a rare inflammatory disease of unknown etiology. AOSD is common in young or middle-aged adults; however, in recent years, there have been increasing reports of elderly AOSD. Differentiating AOSD from diseases such as infections and malignancies is difficult. Moreover, rare fulminant AOSD cases with resistance to corticosteroids and immunosuppressive drugs have been reported. PATIENT CONCERNS: An 80-year-old woman presented with flaccid fever, generalized arthralgia, and erythema of the anterior chest for 2 weeks. On day 5 of hospitalization, the patient developed pleural effusion with hypoxemia and her vital signs indicated rapid progression to shock. During the clinical course, the levels of inflammatory markers, including maximum level of ferritin and white blood cells (WBCs) were elevated (252,796 ng/mL and 86,500/μV, respectively) with disseminated intravascular coagulation syndrome (DIC) and macrophage activation syndrome (MAS). DIAGNOSIS: The patient was diagnosed with elderly AOSD as per the Yamaguchi criteria for AOSD. The state of disease was extremely severe with rapid progression and was, thus, categorized as a fulminant form of elderly AOSD.

interventionsThe patient was treated with prednisolone (PSL) pulse therapy (1000 mg/d) twice and plasma exchange in the intensive care unit for the primary disease and shock. Although she recovered from shock, she developed DIC and MAS. Methotrexate (MTX; 10 mg/d) improved the DIC and MAS. However, severe pleuritis recurred and the patient developed pericarditis; her primary disease was poorly controlled. Finally, tocilizumab (TCZ) was introduced using interleukin-18 (IL-18) as a surrogate marker. The IL-18 level was measured repeatedly following admission, with the peak level (170,000 pg/mL) recorded on the 75th day of hospitalization, immediately prior to introducing TCZ. OUTCOMES: The combined use of MTX, TCZ, and PSL was effective in suppressing elderly AOSD, which was unsuccessfully controlled with MTX and PSL. Frequent monitoring of IL-18 levels proved useful for differentiating elderly AOSD from other diseases. LESSONS: A fulminant form of elderly AOSD was treated with a combination of MTX, TCZ, and PSL. Repeated monitoring of IL-18 levels can be useful for decision-making in treating elderly AOSD.

Indexed as

Disseminated Intravascular CoagulationMacrophage Activation SyndromeStill's Disease, Adult-OnsetAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedFemaleHumansInterleukin-18MethotrexateMiddle AgedNeoplasm Recurrence, LocalPrednisoloneTreatment OutcomeAntibodies, Monoclonal, HumanizedInterleukin-18MethotrexatePrednisolonetocilizumab

Identifiers

PMID35839054
PMCPMC11132312
OpenAlexW4285590106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.